3 news items
Panbela Provides Business Update and Reports Q1 2024 Financial Results
PBLA
15 May 24
in clinical studies of metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 14.6 months and an objective response rate
Panbela Announces Transfer to OTCQB Market
PBLA
16 Apr 24
in clinical studies of metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 14.6 months and an objective response rate (ORR
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
PBLA
26 Mar 24
response rate (ORR) of 48%, both exceeding what is typical for the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary
- Prev
- 1
- Next